Risk Prediction for Individuals by Van Calster, Ben et al.
Copyright 2015 American Medical Association. All rights reserved.
individual patients’ conditions, life expectancy, andvalues to
inform an optimal individualized ICD implantation decision.
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Risk Prediction for Individuals
To theEditorAViewpointbyDrSnidermanandcolleagues1 dis-
cussed how risk estimates from predictionmodels should be
interpreted in the era of predictive analytics.Wewould like to
expand on 2 statements.
First,wedisagree that “probability is notmeaningful in an
individual context.”Historically, the conceptof individual risk
has been vigorously debated. This discussion arises from the
fact that a patientwill orwill not develop the disease or expe-
rience the event of interest. However, risk can be thought of
as the subjective level to which one “believes in” or is “pre-
pared to bet on” the occurrence of a disease or event,2 just as
one bets on future 1-time events in games of sport. Acting on
riskminimizesmistakesandmaximizesclinicaloutcomes:one
must play the odds to be successful.3 Hence, risk assessment
is highly meaningful for the individual.
Second, Snidermanand colleagues stated that riskmodels
areuncertainabouttrueindividualrisk. Indeed,riskmodelsonly
provide an indicationof risk for patientswith similar predictor
values,bothwhendevelopedwithmodernpredictivetechniques
orclassicstatistical regressionanalysis.Wedisagreewiththe im-
plication that this limits the relevanceof riskpredictions for in-
dividuals because a little prediction goes a longway.4
Adding more and more predictors to the model may re-
fine risk assessments, but crucial to the understanding of risk
estimation is the idea of conditioning (ie, which pieces of in-
formationabout thepatientareknownatagiven timeandwere
used in the predictive model). We suggest language such as
“basedonyourage, risk factors, andnoninvasive imaging,your
risk of this cancer is 10%. This riskmay be refined should you
get an invasive biopsy.”
Because models are imperfect, the calibration of risk es-
timates should be assessed carefully in validation studies by
comparing estimated risk with observed outcomes. For ex-
ample, amongpatientswith an estimateddisease risk of 10%,
does 1 in 10 on average have the disease or experience the
event?Calibration should receivemore attention inepidemio-
logical research because this property determines the mod-
el’s potential clinical utility, in combination with themodel’s
discriminative ability.5
Riskprediction is highly relevant for decisionmaking. For
application at the individual level, it is imperative that physi-
cians and patients have a good understanding of the concept
of risk as well as knowing what information was available to
the risk model.
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In ReplyWe agree with Dr Van Calster and colleagues that risk
assessment is valuable in the care of individuals.We stated in
the conclusion of our Viewpoint that “Predictive algorithms
are an essential component of guideline recommendations.”
The phrase about probability not being meaningful in the in-
dividual context wasmisunderstood and not intended to im-
ply that calculating individual risks was not useful.
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Instead, we wanted to direct the reader to the excellent
discussion by Cohen1 of the limitations of the frequentist
notion of probability understood as an estimate of the fre-
quency of a particular event in a total sequence of events.
Basically, we meant that frequentist probability is not verifi-
able in an individual context because a person either experi-
ences or does not experience the event. Consequently, we
agree that calibration is important in the assessment of pre-
dictive model performance.
We are pleased Van Calster and colleagues agree that risk
estimates areuncertain about individual risk. Thismatters be-
causemany guidelines are applied in a binary fashion; there-
fore, if the risk estimate falls above or below a decision line,
potentially lifesaving therapy will or will not be adminis-
tered.We think that highlighting the limitations of individual
risk will help clinicians treat the risk estimate as one impor-
tant component in their practice of care and not a definitive
assessment of their patient’s future. This view is highlighted
by the recent American Heart Association/American College
of Cardiology cholesterol guidelines that consider risk assess-
ment as the first step in an informed discussion between the
patient and his or her physician.2
Van Calster and colleagues expand on our point about
the conditional nature of risk estimates. Paraphrasing their
suggested wording to our cardiovascular example, we would
say “based on your age and standard risk factors, your risk of
experiencing a cardiovascular event in the next 10 years is
10%. This risk may be refined should you obtain your coro-
nary calcium.” This presentation highlights the time horizon
used as another limitation in the application of risk algo-
rithms. Unlike their diagnostic cousins, prognostic models
assess the risk of disease occurring in a prespecified future
time. But treating 40- or 50-year-olds based solely on their
10-year risk of cardiovascular disease may be short-sighted
because low risk may mask nonreversible detrimental
changes occurring in the arterial wall.
We suggest that greater emphasis should beplacedon the
causal factors for the disease. In cardiovascular prevention,
these factors are entered into all conventional algorithms, but
comparedwith age and sex, they play little role in driving the
resulting estimate. Thus, those with earlier, persistent eleva-
tions of cholesterol may be at much greater longer-term risk
than those with intermittent elevations, but these important
differences may not produce meaningfully different esti-
mates of calculated 10-year risk.3
The limitations of prognosticmodelsmean the physician
mustplay avital role in thedecision-makingprocess.As Silver
put it, “Thekey is in remembering that amodel is a tool tohelp
us understand the complexities of the universe, and never a
substitute for the universe itself.”4
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